Gilead Sciences (GILD +4.7%) is one of the best performers in the S&P 500 today after...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences (GILD +4.7%) is one of the best performers in the S&P 500 today after JPMorgan analyst Geoff Meacham came out with some positive comments about the company's new HIV medication Stribild and hepatitis C drug program, and raised his price target to $75 from $70.